ToolGen Incorporated Logo

ToolGen Incorporated

Biotechnology company developing genome editing for therapeutics and agriculture.

199800 | KO

Overview

Corporate Details

ISIN(s):
KR7199800004
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙로 172 바이오이노베이션파크,8층, 강서구

Description

ToolGen Incorporated is a biotechnology company specializing in the development and application of genome editing technology. Founded in 1999, the company has developed multiple generations of gene editing tools, including Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and the CRISPR-Cas9 system. ToolGen is a key patent holder for CRISPR-Cas9 technology, being the first to file a patent for its application in eukaryotic cells. The company's business model focuses on developing therapeutics and agricultural products, as well as monetizing its intellectual property through licensing and collaborations. Its primary mission is to translate genetic knowledge into transformative products for biomedicine and agriculture.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-01-06 00:00
[기재정정]신규시설투자등
Korean 11.7 KB
2022-12-22 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 30.3 KB
2022-12-22 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 31.5 KB
2022-12-15 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2022-11-22 00:00
기업설명회(IR)개최
Korean 7.3 KB
2022-11-14 00:00
분기보고서 (2022.09)
Korean 1.7 MB
2022-11-04 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.1 KB
2022-11-04 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.1 KB
2022-09-23 00:00
본점소재지변경
Korean 5.0 KB
2022-08-16 00:00
반기보고서 (2022.06)
Korean 1.7 MB
2022-08-08 00:00
주식등의대량보유상황보고서(약식)
Korean 55.6 KB
2022-08-04 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.0 KB
2022-06-29 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 30.2 KB
2022-05-10 00:00
분기보고서 (2022.03)
Korean 1.6 MB
2022-03-31 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.6 KB

Automate Your Workflow. Get a real-time feed of all ToolGen Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ToolGen Incorporated

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ToolGen Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CAMBRIDGE COGNITION HOLDINGS PLC Logo
Develops digital solutions and a platform for CNS clinical trials to assess brain health.
United Kingdom
COG
A clinical-stage biopharmaceutical company developing novel cancer therapeutics.
Japan
4575
Captor Therapeutics S.A. Logo
Develops Targeted Protein Degradation therapies for cancer and autoimmune diseases.
Poland
CTX
Cardiff Oncology, Inc. Logo
A clinical-stage biotech developing cancer therapies that inhibit Polo-like kinase 1.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
Develops AI-powered epigenetic and genetic tests for early heart disease detection.
United States of America
CDIO
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing treatments for Central Nervous System disorders.
United States of America
SAVA
Celcuity Inc. Logo
Clinical-stage biotech developing targeted therapies for multiple solid tumors.
United States of America
CELC
Develops and manufactures cellulose-based nonwoven fabrics for the cosmetics sector.
South Korea
318160
CEL SCI CORP Logo
Clinical-stage biotech developing immunotherapies for cancer and infectious diseases.
United States of America
CVM
Celyad Oncology SA Logo
Biotechnology company developing innovative CAR-T cell therapies to treat cancer.
Belgium
CYAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.